医药行业周报：Teva氘丁苯那嗪缓释片在华申报上市

Investment Rating - The report does not provide specific ratings for the chemical pharmaceuticals and traditional Chinese medicine industries, while the biopharmaceutical sector is rated as Neutral [1][7]. Core Insights - The pharmaceutical sector showed a performance increase of +1.32% on November 11, 2024, outperforming the CSI 300 index by 0.66 percentage points, ranking 12th among 31 sub-industries [3]. - Notable sub-industry performances include vaccines (+3.27%), medical research outsourcing (+3.16%), and medical devices (+1.79%), while offline pharmacies (-0.25%) and blood products (+0.65%) lagged behind [3]. - Teva's application for the new drug deuterated benztropine sustained-release tablets has been accepted for market entry in China, indicating potential growth in the sector [4]. Summary by Sections Market Performance - On November 11, 2024, the pharmaceutical sector's increase of +1.32% outperformed the CSI 300 index, with specific sub-industries like vaccines and medical devices showing strong growth [3]. Company News - Teva's deuterated benztropine sustained-release tablets have been accepted for market entry in China, which could enhance the company's market position [4]. - Several companies, including Xinhua Pharmaceutical and Hualu Pharmaceutical, received approval for new drug registrations, indicating ongoing innovation and regulatory compliance in the industry [4].